1,165 press releases in English indexed under food & drink.
ROCHESTER, N.Y., Oct. 12, 2026 -- Rochester Midland Corporation ("Rochester Midland"), a leading provider of route-based, technical services and specialty chemical products across water treatment, food safety and other verticals, today announced that it has acquired ApHinity...
Boca Raton, Florida Monday Oct 12, 2026 @ 6:00 AM Eastern — From the home improvement aisles of Home Depot to the shelves of Walmart and the online marketplace of Amazon, Mitch Gould has spent decades helping consumer product companies navigate the American retail industry. For Gould, a Brooklyn native whose family roots run deep in manufacturing and distribution, the journey has been about more than selling products. It has been about building relationships, recognizing opportunities, and understanding what it takes to bring brands into some of the world's most competitive retail environments. Gould's career has included working with major national retailers such as Home Depot, Lowe's, Walmart, Costco, CVS, Walgreens, GNC, and Amazon. Along the way, he has helped manufacturers and consumer brands pursue distribution opportunities across multiple product categories, from hardware and household goods to health, wellness, and sports nutrition. Learning the Business in Brooklyn Gould's introduction to retail began long before his first meeting with a national retail buyer. Growing up in Brooklyn, he learned the fundamentals of manufacturing, sales, and distribution from his father and grandfather, both of whom worked in the consumer products business. Those early experiences gave him an understanding of how products move from manufacturers to distributors, retailers, and ultimately consumers. "Retail was part of my life long before it became my career," said Mitch Gould. "My grandfather had a factory in Brooklyn and a showroom in the Empire State Building. My father Jerry carried that tradition forward in manufacturing and distribution. I grew up learning how products were made, how they were sold, and how relationships opened doors. Those lessons stayed with me throughout my career." The lessons proved valuable as Gould began developing relationships with major retailers and helping companies expand their distribution networks. His career eventually brought him into contact with some of the largest names in American retail, including Home Depot, where early relationships helped establish opportunities that would influence his career for years to come. From Home Improvement to Mass-Market Retail As Gould's career developed, so did the range of retailers and product categories he worked with. Home Depot and Lowe's represented opportunities in the home improvement sector, while Walmart and Costco provided access to mass-market consumers. Pharmacy chains such as CVS and Walgreens, along with specialty retailers like GNC, introduced different distribution requirements and opportunities for health and wellness brands. Each retail environment presented its own challenges, from product selection and packaging to pricing, logistics, and merchandising. Gould's experience across these channels gave him a broad perspective on the American retail landscape and the differences between introducing a product to a specialty retailer and preparing it for national distribution. His career has also included work with established consumer product companies and brands, including Rubbermaid, Sunbeam, Igloo, and Miracle-Gro. "I've had the opportunity to help brands get their products into some of the biggest retailers in America, from Home Depot and Lowe's to Walmart, Costco, CVS, and Walgreens," Gould said. "Every retailer is different. You have to understand what their buyers are looking for, what their customers want, and how to make the product work for that particular store. That's something you learn through experience, not from a textbook." Amazon Opens a New Chapter As retail evolved, Gould's experience expanded from traditional brick-and-mortar distribution into e-commerce. One of the notable chapters in his career involved Amazon's developing sports nutrition business. Working with Muscle Foods and Amazon buyers, Gould helped introduce more than 100 sports nutrition brands and products to the online marketplace, contributing to the early development of a category that would become an established part of Amazon's health and wellness offerings. The experience represented a natural progression in Gould's career, applying decades of product distribution knowledge to a new retail model. Although Amazon changed the way consumers discovered and purchased products, Gould recognized that many of the underlying principles of successful distribution remained the same: product selection, pricing, inventory, reliable fulfillment, and understanding customer demand. "When I started in this business, everything revolved around getting products onto store shelves," Gould said. "Then Amazon came along and changed the retail landscape. I had the opportunity to help build its sports nutrition category, bringing more than 100 brands and products to the platform. It was a different way of doing business, but the relationships, product knowledge, and distribution experience I'd developed over the years were just as valuable." A Brooklyn Foundation for a National Retail Career Throughout his career, Gould has worked with manufacturers, entrepreneurs, and consumer brands seeking opportunities in the United States. His experience reflects the transformation of American retail, from the dominance of national brick-and-mortar chains to the emergence of e-commerce platforms that allow brands to reach consumers across the country. For Gould, the common thread has been the business education he received growing up in Brooklyn and the relationships he developed throughout his career. From Home Depot and Walmart to Amazon, his professional journey illustrates how a foundation in traditional manufacturing and distribution can translate into opportunities across generations of American retail. About Mitch Gould Mitch Gould is a third-generation retail distribution and manufacturing expert with more than 25 years of experience launching and scaling consumer products across sports nutrition, health and wellness, skincare, hardware, and beverages. He has worked with iconic consumer brands such as Igloo, Rubbermaid, Sunbeam, and Miracle-Gro, as well as high-profile celebrity brands including Steven Seagal, Hulk Hogan, Chuck Liddell, 8× Mr. Olympia Ronnie Coleman, and martial arts pioneer Bob Wall. Over the course of his career, Gould has played a key role in helping shape the growth of the U.S. sports nutrition category-supporting the expansion of performance-focused products across major retail and e-commerce platforms, including Amazon, Walmart, GNC, CVS, and Walgreens. His work has centered on bringing muscle-building, recovery, and performance-oriented products to a broader consumer audience.
Boca Raton, Florida Monday Oct 12, 2026 @ 5:00 AM Eastern — DuLac Farmaceutici is following up with prospective retail and distribution partners after participating in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, held September 14-17 in Palm Beach Gardens, Florida. This event is marking another step in the Italian pharmaceutical company's effort to build a broader U.S. retail presence beyond its established Amazon business. The event provided an opportunity to discuss DuLac’s Italian-developed portfolio with buyers across health, specialty, food, drug and mass retail channels. The company is now continuing those conversations to explore product assortment and distribution opportunities in the United States. DuLac’s portfolio includes its high-concentration Arnica Gel 98% range, topical leg-care products, and the Dinaven and Diosmin lines. The portfolio reflects the company’s Italian manufacturing expertise, botanical formulation capabilities, and more than 30 years of pharmaceutical industry experience. Building on an Existing E-Commerce Presence DuLac enters these discussions with products already available to U.S. consumers through its Amazon storefront and OneLavi. Customer feedback provides an additional point of reference for prospective partners: The company’s Arnica Gel 98% listing on Amazon.com has an average customer rating of 4.5 out of 5 stars, offering prospective partners a reference point for consumer feedback as they evaluate the portfolio. "Our priority following ECRM is to work with prospective partners to identify the DuLac products that best fit their customers and channels,” said Gabriele Bollani, Founder and CEO of DuLac Farmaceutici. “We want to build lasting relationships by combining our Italian formulation and manufacturing expertise with a clear understanding of each partner’s commercial needs.” Italian Expertise Behind the Portfolio During the meetings, DuLac introduced buyers to the research and manufacturing approach behind its products, including its proprietary Arnica Montana Arricchita™ project and its work with botanical ingredients and advanced extraction technologies. The company’s European pharmacy heritage and Italian production provide the foundation for its portfolio. Follow-up discussions will focus on the products relevant to each prospective partner, their positioning and the requirements for a potential launch. U.S. Retail and Distribution Opportunities Following ECRM, DuLac is continuing discussions with prospective partners to assess product assortment, channel fit and distribution opportunities, while building on its existing U.S. e-commerce presence. The company's long-term objective is to establish DuLac as a nationally recognized U.S. brand across multiple channels, combining its European pharmacy heritage and Italian manufacturing with the consumer traction it has already established in the American market. About DuLac Farmaceutici DuLac Farmaceutici is an Italian pharmaceutical company specializing in dermo-cosmetic products developed through pharmaceutical-grade manufacturing standards. Built on more than 30 years of pharmaceutical industry expertise, the company combines botanical innovation, advanced extraction technologies, and modern manufacturing to create Italian-developed products for international markets. DuLac products are developed and manufactured in Italy using rigorous quality and sustainability standards. Learn more at DuLac Farmaceutici USA, through the company's Amazon Storefront, and on OneLavi.
LONDON, Oct. 12, 2026 -- Constellation Cold Logistics ("Constellation"), a leading European provider of temperature-controlled storage and logistics solutions, today announced the acquisition of Impruv Logistics AS ("Impruv"), a Norwegian cold storage and food logistics...
- A single journey through the food, travel and culture of Mungyeong, Pohang, Gyeongju and Andong…showcasing Gyeongbuk's appeal to global audiences 「K-FOOD: Gyeongbuk Edition」 Premieres on Arirang TV on October 14 at 9:00 a.m. (KST) Airs every Wednesday at 9:00 a.m. (KST) for four weeks....
New York, New York--(October 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Simply Good Foods Company (NASDAQ: SMPL) between October 24, 2024 and April 8, 2026, inclusive (the "Class Period"), of the important October 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased Simply Good Foods common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks1,2 UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated3,4 The FDA has accepted Roche's Biologics License Application (BLA), with an approval decision expected by July 2027 Basel, 10 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness (swelling in the back of the eye due to retinal fluid) with vamikibart treatment. The data were presented at the American Academy of Ophthalmology 2026 Annual Meeting (AAO 2026) in New Orleans, LA.1 Additionally, the U.S. Food and Drug Administration (FDA) has accepted Roche’s Biologics License Application (BLA) for vamikibart for the treatment of UME. The filing acceptance is based on the results from the MEERKAT and SANDCAT studies. The FDA is expected to make a decision on approval by July 2027. If approved, vamikibart would be the first non-steroid targeted treatment for UME, with potential to establish a new standard of care. Regulatory submissions have also been filed and accepted in the European Union, China and Japan. “These one-year results strengthen vamikibart’s clinical profile, confirming that initial visual and anatomical improvements are maintained over 52 weeks,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The acceptance of our application by the FDA and other regulatory bodies around the world brings us closer to offering a transformative, non-steroid therapy for people living with this sight-threatening condition.” “Currently, UME is commonly treated with off-label therapies or ocular steroids, the latter carrying significant long-term side effects like glaucoma and cataract formation,” said Nisha Acharya, M.D., M.S., Distinguished Professor of Ophthalmology at UCSF and Director of the Uveitis and Ocular Inflammatory Disease Service. “Vamikibart is the first non-steroid targeted therapy to demonstrate meaningful and sustained visual and anatomical improvements in people with UME, offering a potential new treatment option that directly targets the inflammation driving this sight-threatening condition.” The 16-week primary analysis results were presented at the AAO meeting in October 2025.2 In both MEERKAT and SANDCAT at 52 weeks, a numerically higher proportion of vamikibart-treated patients achieved vision gains compared to sham treatment on the primary endpoint. Key secondary endpoints showed this benefit was maintained, with sustained improvements in average change from baseline in best corrected visual acuity (BCVA) and average change from baseline in central subfield thickness (CST), a key measure of macular edema. Vamikibart demonstrated durable clinical benefit with a low treatment burden: approximately two-thirds of eligible patients required no retreatment after 16 weeks, while the majority of those who did required only one additional injection. Vamikibart was well tolerated, maintaining a favourable safety profile, with a low incidence of treatment-related ocular adverse events (AEs) and intraocular inflammation (IOI) events.1 UME is the leading cause of moderate-to-severe vision loss in individuals with uveitis, predominantly affecting working-age adults.3,4 Approximately 20% of UME patients progress to sustained blindness within three years of diagnosis.5 Standard-of-care treatments, primarily high-dose or local corticosteroids, carry substantial long-term risks, including secondary cataracts and elevated intraocular pressure leading to glaucoma.6-11 As a targeted anti-IL-6 monoclonal antibody, vamikibart is being developed to address these clinical unmet needs and deliver sustained visual preservation.1,12 About the MEERKAT and SANDCAT studies MEERKAT (NCT05642312) and SANDCAT (NCT05642325) are identical Phase III, global, parallel, multicentre, randomised, double-masked, sham comparator-controlled, 52-week trials of intravitreal (IVT) vamikibart in uveitic macular edema (UME). In both trials, patients were randomised and received treatment every four weeks with either 0.25 mg vamikibart, 1 mg vamikibart or sham IVT injection, for up to 16 weeks, followed by PRN treatment through week 52. The primary endpoint of both Phase III trials was the proportion of participants with a 15 letter or more improvement from baseline in best corrected visual acuity (BCVA) at week 16. Key secondary endpoints included the average change from baseline in BCVA and CST at week 16. The safety of vamikibart was assessed through adverse events (AEs) such as treatment related ocular AEs, intraocular inflammation (IOI) and retinal occlusive vasculitis. The studies included participants with and without prior IVT treatment history and included patients with history of raised IOP and glaucoma.2,13,14 About uveitic macular edema (UME) UME is characterised by the buildup of fluid in the macula due to uveitis, an inflammatory eye condition.3 Although rare compared to other eye diseases, UME has a disproportionate impact on vision loss and blindness globally.3,15-20 It is the leading cause of moderate and severe vision loss in people with uveitis, and the most frequent sight threatening complication in uveitis.17-22 Uveitis accounts for 10% to 20% of blindness in the United States and Europe, and up to 25% of blindness in the developing world.23 UME has a significant negative impact on people's quality of life, including physical and mental health, social functioning, and visual function for day-to-day activities such as driving and reading.22,24,25 Steroids, the current standard of care for UME, are associated with significant serious side effects such as increased pressure in the eye, glaucoma and cataracts, and have recognised efficacy limitations.6-11 About vamikibart Vamikibart is an investigational monoclonal antibody that has been specifically engineered for IVT administration.1,2,12 It targets interleukin-6 (IL-6), a key cytokine in the inflammatory pathway in UME.1,2,12 In the Phase I DOVETAIL study, vamikibart provided rapid vision improvements and resolution of macular edema in people with UME.12 Vamikibart was also well tolerated, with no treatment-related serious adverse events reported.12 Based on the promising Phase I DOVETAIL data, Roche initiated the two identical Phase III vamikibart studies MEERKAT and SANDCAT.1,2,12 Vamikibart is being investigated in retinal diseases with recognised inflammatory pathways. Vamikibart has orphan drug designation in the United States and European Union. About Roche in Ophthalmology At Roche, we are on a mission to save and restore eyesight. Over 330 million people around the world are blind, or living with vision loss, creating a profound personal and socioeconomic burden. With the broadest pipeline in Ophthalmology, we continue to invest at scale to redefine what is medically possible in eye care. Our comprehensive ophthalmology pipeline integrates diverse targets, advanced delivery systems, cell and gene therapies, and AI-augmented imaging capabilities, targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Acharya N, et al. Vamikibart for Uveitic Macular Edema: Week 52 Efficacy and Safety Results From the Phase 3 MEERKAT and SANDCAT Trials. Presented at: the American Academy of Ophthalmology Annual Meeting (AAO 2026); 2026 October 10; New Orleans, Louisiana, United States. [2] Khurana RN, et al. Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: First Report of Phase 3 MEERKAT/SANDCAT Trials. Presented at: the American Academy of Ophthalmology Annual Meeting (AAO 2025); 2025 October 17; Orlando, Florida, United States. [3] Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol. 2019;13:1761-1777. doi:10.2147/OPTH.S180580 [4] Jones NP, Pradeep A, John B. Certification of vision impairment in patients with uveitis attending a specialist clinic. Ocul Immunol Inflamm. 2019;27(4):540-544. doi:10.1080/09273948.2018.1441874 [5] Do BK, et al. Visual Outcomes by Age and Sex in Uveitic Macular Edema: Real-World Retina Registry Analysis. Presented at: the 44th Annual Meeting of the American Society of Retinal Specialists; 2026 July 15–18; Montréal, Canada. [6] Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Semin Arthritis Rheum. 2019;49(3):438-445. doi:10.1016/j.semarthrit.2019.06.004 [7] Leandro L, Beare N, Bhan K, et al. Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study. Eye. 2021;35(12):3342-3349. doi:10.1038/s41433-020-01336-6 [8] Nguyen QD, Hatef E, Kayen B, et al. A Cross-sectional Study of the Current Treatment Patterns in Noninfectious Uveitis among Specialists in the United States. Ophthalmology. 2011;118(1):184-190. doi:10.1016/j.ophtha.2010.03.029 [9] Fini ME, Schwartz SG, Gao X, et al. Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res. 2017;56:58-83. doi:10.1016/j.preteyeres.2016.09.003 [10] Sen HN, Vitale S, Gangaputra SS, et al. Periocular Corticosteroid Injections in Uveitis: Effects and Complications. Ophthalmology. 2014;121(11):2275-2286. doi:10.1016/j.ophtha.2014.05.021 [11] Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clinical Therapeutics. 2017;39(11):2216-2229. doi:10.1016/j.clinthera.2017.09.011 [12] Sharma S, Lin P, Hu A, et al. Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial. JAMA Ophthalmol. 2026;144(5):442-451. doi:10.1001/jamaophthalmol.2026.0610 [13] Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema. clinicaltrials.gov; 2025. Accessed September 17, 2026. https://clinicaltrials.gov/study/NCT05642312 [14] Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema. clinicaltrials.gov; 2026. Accessed September 17, 2026. https://clinicaltrials.gov/study/NCT05642325 [15] Teper SJ. Update on the Management of Uveitic Macular Edema. J Clin Med. 2021;10(18):4133. doi:10.3390/jcm10184133 [16] Fardeau C, Champion E, Massamba N, LeHoang P. Uveitic macular edema. Eye. 2016;30(10):1277-1292. doi:10.1038/eye.2016.115 [17] Smith JR, Thorne JE, Flaxel CJ, et al. Treatment of Noninfectious Uveitic Macular Edema with Periocular and Intraocular Corticosteroid Therapies: A Report by the American Academy of Ophthalmology. Ophthalmology. 2024;131(9):1107-1120. doi:10.1016/j.ophtha.2024.02.019 [18] Sood G, Patel BC. Uveitic Macular Edema. In: StatPearls. StatPearls Publishing; 2023. Accessed September 17, 2026. http://www.ncbi.nlm.nih.gov/books/NBK562158/ [19] Tomkins-Netzer O, Lightman SL, Burke AE, et al. Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. Ophthalmology. 2021;128(5):719-728. doi:10.1016/j.ophtha.2020.08.035 [20] Matas J, Llorenç V, Fonollosa A, et al. Systemic Regulatory T Cells and IL-6 as Prognostic Factors for Anatomical Improvement of Uveitic Macular Edema. Front Immunol. 2020;11:579005. doi:10.3389/fimmu.2020.579005 [21] Tomkins-Netzer O, Talat L, Bar A, et al. Long-Term Clinical Outcome and Causes of Vision Loss in Patients with Uveitis. Ophthalmology. 2014;121(12):2387-2392. doi:10.1016/j.ophtha.2014.07.007 [22] Tallouzi MO, Moore DJ, Bucknall N, et al. Outcomes important to patients with non-infectious posterior segment-involving uveitis: a qualitative study. BMJ Open Ophth. 2020;5(1):e000481. doi:10.1136/bmjophth-2020-000481 [23] Cunningham ET, Zierhut M. Vision Loss in Uveitis. Ocular Immunology and Inflammation. 2021;29(6):1037-1039. doi:10.1080/09273948.2021.2017152 [24] Tomkins-Netzer O, Lightman S, Drye L, et al. Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results. Ophthalmology. 2015;122(11):2351-2359. doi:10.1016/j.ophtha.2015.07.036 [25] Frick KD, Drye LT, Kempen JH, et al. Associations among Visual Acuity and Vision- and Health-Related Quality of Life among Patients in the Multicenter Uveitis Steroid Treatment Trial. Invest Ophthalmol Vis Sci. 2012;53(3):1169. doi:10.1167/iovs.11-8259 Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone: +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com Attachment Media Investor Release Vamikibart in UME English
New York, New York--(October 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Simply Good Foods Company (NASDAQ: SMPL) between October 24, 2024 and April 8, 2026, inclusive (the "Class Period"), of the important October 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased Simply Good Foods common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
If you purchased or acquired Simply Good Foods common stock between October 24, 2024 and April 8, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
Shenzhen, China, Oct. 10, 2026 -- Shenzhen Ninenovo Technology Limited, the parent company of RingConn, announced that its Smart Ring has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for non-invasive blood oxygen (SpO2) measurement (Clearance No....
From its head office in Mindemoya on Manitoulin Island, Ontario, Wahl Water has supplied water treatment equipment to Canadian property owners for more than 30 years. The company works with households and seasonal cottages, as well as small businesses that serve water to the public, such as restaurants and campgrounds. Most of its customers draw […]
Vancouver, British Columbia--(October 9, 2026) - Purebread Brands Inc. (TSXV: BRED) ("Purebread Brands" or the "Company") and Caffè Artigiano today announced they have signed a letter of intent with an arms' length party under which Purebread Brands proposes to acquire Caffè Artigiano's café business, including its corporate and franchise operations in Canada.The proposed transaction would bring together two established British Columbia bakery and café brands and significantly...